利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

76 条记录 (耗时 0.036 秒)

    Method of enhancing blood flow in tissue
    41.
    发明授权
    Method of enhancing blood flow in tissue 失效
    增加组织中血流量的方法

    公开(公告)号：US06263880B1

    公开(公告)日：2001-07-24

    申请号：US09337622

    申请日：1999-06-21

    申请人： Theodore L. Parker ,  Danforth Joslyn ,  Serjan D. Nikolic

    发明人： Theodore L. Parker ,  Danforth Joslyn ,  Serjan D. Nikolic

    IPC分类号： A61F202

    CPC分类号： A61K9/0024 ,  A61F2/02 ,  A61F2/2493 ,  A61F2/95 ,  A61F2210/0004 ,  A61F2250/0067

    摘要： Method of enhancing blood flow in tissue wherein an implant is non-ablatively introduced into the tissue in order to stimulate production of angiogenic agents by the tissue, the agents produced by the tissue are absorbed into the implant, where they are stored, and the stored agents are released back into the tissue when the production of agents by the tissue subsides. The implant is fabricated of a bioresorbable material and is resorbed into the tissue after the agents are released. In some embodiments, an exogenous angiogenic agent in included in the implant and released into the tissue along with the agents which are produced by the tissue and absorbed by the implant.

    摘要翻译： 增强组织中血液流动的方法，其中将植入物非消融性地引入组织中以刺激组织产生血管生成剂，由组织产生的药剂被吸收到植入物中，并存储在其中 当组织的制剂生产减少时，药剂释放回组织。 植入物由生物可再吸收材料制成，并且在药剂释放后被吸收到组织中。 在一些实施方案中，包含在植入物中的外源性血管生成剂以及由组织产生并由植入物吸收的药剂释放到组织中。

    Phosphonium salts
    43.
    发明授权
    Phosphonium salts 失效
    鏻盐

    公开(公告)号：US5105006A

    公开(公告)日：1992-04-14

    申请号：US358319

    申请日：1989-05-25

    申请人： Theodore L. Parker

    发明人： Theodore L. Parker

    IPC分类号： C07F9/54 ,  C08G59/62 ,  C08G59/68 ,  C08L63/00

    CPC分类号： C08G59/688 ,  C07F9/54 ,  C08G59/621 ,  C08L63/00

    摘要： The invention is a novel phosphonium salt, useful as an initiator or catalyst in the reaction of oxirane groups in an epoxy resin with aromatic carbonate and/or ester linkages in monomeric, oligomeric, or polymeric carbonates, esters, or estercarbonates.

    摘要翻译： 本发明是一种新颖的鏻盐，可用作环氧树脂中环氧乙烷基团与单体，低聚或聚合碳酸酯，酯或碳酸酯中的芳族碳酸酯和/或酯键反应的引发剂或催化剂。

    Plastic optical fiber for in vivo use having a biocompatible polyurethane cladding
    44.
    发明授权
    Plastic optical fiber for in vivo use having a biocompatible polyurethane cladding 失效
    用于体内使用的塑料光纤具有生物相容的聚氨酯包层

    公开(公告)号：US4893897A

    公开(公告)日：1990-01-16

    申请号：US163056

    申请日：1988-03-02

    申请人： Theodore L. Parker ,  David R. Pedersen ,  Jerry D. Moseley

    发明人： Theodore L. Parker ,  David R. Pedersen ,  Jerry D. Moseley

    IPC分类号： G02B1/04

    CPC分类号： G02B6/02033 ,  G02B1/046 ,  G02B1/048

    摘要： The present invention pertains to a flexible organic polymeric optical fiber core having an adherent flexible organic polymeric cladding on the outer surface. Preferably, the polymeric core has a refractive index which is at least 0.01 units greater than the refractive index of the polymeric polyurethane cladding. More particularly, the invention relates to an organic polymeric optical fiber for in vivo use in the tissue of a living mammal, preferably a human being. In addition to compatibility in live tissue and body fluids, such a fiber must be capable of repeatedly being deformed in a small bend radius without losing the ability to transmit light. The clad optical fibers are useful to measure levels of components (e.g. pH, oxygen, carbon dioxide) in moving living tissue, such as the heart or lungs.

    摘要翻译： 本发明涉及在外表面上具有粘附的柔性有机聚合物包层的柔性有机聚合物光纤芯。 优选地，聚合物芯具有比聚合物聚氨酯包层的折射率大至少0.01个单位的折射率。 更具体地说，本发明涉及用于活体哺乳动物（优选人）组织中体内使用的有机聚合物光纤。 除了在活体组织和体液中的相容性之外，这种纤维必须能够以小的弯曲半径重复变形，而不会失去透光能力。 包层光纤可用于测量移动的活体组织（例如心脏或肺）中的组分（例如pH，氧气，二氧化碳）的水平。

    Isocyanate adducts with benzoxazolones or benzoxazinediones and use thereof as latent chain extenders or cross-linkers for epoxides
    46.
    发明授权
    Isocyanate adducts with benzoxazolones or benzoxazinediones and use thereof as latent chain extenders or cross-linkers for epoxides 失效
    异氰酸酯与苯并恶唑酮或苯并恶嗪二酮的加合物及其用作环氧化物的潜在链增长剂或交联剂

    公开(公告)号：US4701512A

    公开(公告)日：1987-10-20

    申请号：US792384

    申请日：1985-10-29

    申请人： Theodore L. Parker

    发明人： Theodore L. Parker

    IPC分类号： C08G18/58 ,  C08G18/80 ,  C08G59/40 ,  C08G71/04

    CPC分类号： C08G18/58 ,  C08G18/807 ,  C08G59/4028

    摘要： The adducts of isocyanates wtih benzoxazolones or benzoxazinediones are novel compounds which may be employed as blocked isocyanates and are particularly useful as latent, epoxide curing agents. At typical epoxide curing temperatures, the isocyanate is oxirane or hydroxyl reactive and the benzoxazole or benzoxazinedione acts like a di- or trifunctional phenol, respectively.

    摘要翻译： 苯并恶唑酮或苯并恶嗪二酮的异氰酸酯的加合物是可用作封闭的异氰酸酯的新型化合物，并且特别用作潜在的环氧化物固化剂。 在典型的环氧化物固化温度下，异氰酸酯是环氧乙烷或羟基反应性的，苯并恶唑或苯并恶嗪二酮分别像二 - 或三官能苯酚一样起作用。

    E beam sterilization of medical devices comprising bioactive coating
    47.
    发明授权
    E beam sterilization of medical devices comprising bioactive coating 有权
    包括生物活性涂层的医疗装置的E束灭菌

    公开(公告)号：US08887477B2

    公开(公告)日：2014-11-18

    申请号：US12619118

    申请日：2009-11-16

    申请人： Robert Falotico ,  Chengxue Li ,  Thai M. Nguyen ,  Theodore L. Parker ,  Jonathon Z. Zhao

    发明人： Robert Falotico ,  Chengxue Li ,  Thai M. Nguyen ,  Theodore L. Parker ,  Jonathon Z. Zhao

    IPC分类号： B65B31/00 ,  B65B55/00 ,  B65B55/16 ,  A61L2/08 ,  B65D81/26

    CPC分类号： B65B31/00 ,  A61L2/087 ,  A61L2202/21 ,  B65B55/00 ,  B65B55/16 ,  B65D81/266

    摘要： The invention provides a method for single-step terminal sterilization process for bio-active heparin coatings on materials and biomaterials containing heparin used in medical devices, such as catheters, tissue engineering scaffolds, or drug delivery carrier materials. This may include any medical device or implantable that could benefit from improved antithrombotic and biocompatible heparin surfaces. Other relevant device examples may include heparin or a heparin derivative coated stents to reduce clotting and restenosis, dental or ophthalmological implants. These materials may comprise additional polymeric compositions such as polyethyleneimine, dextran sulfate or their modified forms. These polymers together with heparin coatings may be applied to other substrate of medical devices such as metal, ceramics or biologically derived materials.

    摘要翻译： 本发明提供了一种用于生物活性肝素涂层在包含用于医疗装置例如导管，组织工程支架或药物递送载体材料中的肝素的材料和生物材料上的单步末端灭菌方法。 这可以包括可以从改进的抗血栓形成和生物相容性肝素表面中受益的任何医疗装置或植入物。 其它相关装置实例可包括肝素或肝素衍生物涂层支架以减少凝血和再狭窄，牙科或眼科植入物。 这些材料可以包含另外的聚合物组合物，例如聚乙烯亚胺，硫酸葡聚糖或其改性形式。 这些聚合物与肝素涂层一起可以应用于诸如金属，陶瓷或生物衍生的材料的医疗装置的其它基底上。

    LOCAL VASCULAR DELIVERY OF ADENOSINE A2A RECEPTOR AGONISTS IN COMBINATION WITH OTHER AGENTS TO REDUCE MYOCARDIAL INJURY
    48.
    发明申请
    LOCAL VASCULAR DELIVERY OF ADENOSINE A2A RECEPTOR AGONISTS IN COMBINATION WITH OTHER AGENTS TO REDUCE MYOCARDIAL INJURY 审中-公开
    局部血管输送腺苷A2A受体激动剂与其他药剂联合减少心肌损伤

    公开(公告)号：US20120130481A1

    公开(公告)日：2012-05-24

    申请号：US12971083

    申请日：2010-12-17

    申请人： Robert Falotico ,  Andrew Luk ,  Theodore L. Parker ,  Jonathon Z. Zhao

    发明人： Robert Falotico ,  Andrew Luk ,  Theodore L. Parker ,  Jonathon Z. Zhao

    IPC分类号： A61F2/82

    CPC分类号： A61L31/022 ,  A61L31/06 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/416 ,  A61L2300/434 ,  A61L2300/436 ,  A61L2300/608 ,  A61L2300/61 ,  C08L67/04 ,  C08L33/10 ,  C08L31/04

    摘要： A stent or other implantable medical device for the local delivery of a selective adenosine receptor agonist may be utilized in combination with other therapeutic agents to reduce myocardial injury following an acute myocardial infarction. As soon as possible following an acute myocardial infarction a stent or other suitable device comprising and capable of delivering a selective adenosine receptor agonist is positioned in the blood vessel with the occlusion responsible for causing the infarct. Once in position , the stent or other intraluminal device is deployed to remove the occlusion and reestablish blood flow to the specific area, region or tissue volume of the heart. Over a given period of time the selective adenosine receptor agonist alone or in combination with other therapeutic agents elute from the stent or other device into the downstream coronary blood flow into the hypoxic cardiac tissue for a time sufficient to reduce the level of myocardial injury.

    摘要翻译： 用于局部递送选择性腺苷受体激动剂的支架或其它可植入医疗装置可与其它治疗剂组合使用以减少急性心肌梗塞后的心肌损伤。 在急性心肌梗死后，尽快地将包含能够递送选择性腺苷受体激动剂的支架或其它合适的装置置于血管中，其中负责引起梗死的闭塞。 一旦就位，支架或其他管腔内装置被部署以去除闭塞并重新建立血液流到心脏的特定区域，区域或组织体积。 在给定的时间段内，单独的或与其它治疗剂组合的选择性腺苷受体激动剂从支架或其他装置洗脱到进入缺氧心脏组织的下游冠状动脉血液中足以降低心肌损伤水平的时间。

    ADHESION PROMOTING PRIMER FOR COATED SURFACES
    49.
    发明申请
    ADHESION PROMOTING PRIMER FOR COATED SURFACES 审中-公开
    涂层表面的粘合剂促进剂

    公开(公告)号：US20110029070A1

    公开(公告)日：2011-02-03

    申请号：US12906295

    申请日：2010-10-18

    申请人： Vipul Dave ,  Robert Falotico ,  Chengxue Li ,  Thai M. Nguyen ,  Theodore L. Parker ,  Jonathon Z. Zhao

    发明人： Vipul Dave ,  Robert Falotico ,  Chengxue Li ,  Thai M. Nguyen ,  Theodore L. Parker ,  Jonathon Z. Zhao

    IPC分类号： A61F2/82 ,  B05D7/00

    CPC分类号： A61F2/91 ,  A61F2/915 ,  A61F2002/91558 ,  A61F2250/0043 ,  A61F2250/0068 ,  A61L31/10 ,  A61L31/16

    摘要： An expandable medical device includes a plurality of elongated struts, forming a substantially cylindrical device which is expandable from a first diameter to a second diameter. A plurality of different beneficial agents may be loaded into different openings within the struts for delivery to the tissue. For treatment of conditions such as restenosis, different agents are loaded into different openings in the device to address different biological processes involved in restenosis and are delivered at different release kinetics matched to the biological process treated. The different agents may also be used to address different diseases from the same drug delivery device. In addition, anti-thrombotic agents may be affixed to at least a portion of the surfaces of the medical device for the prevention of sub-acute thrombosis. To ensure that the different agents remain affixed to the device as well as to each other, primer layers may be utilized.

    摘要翻译： 可扩张医疗装置包括多个细长的支柱，形成从第一直径扩展到第二直径的基本上圆柱形的装置。 多个不同的有益剂可以被装载到支柱内的不同开口中，以便输送到组织。 为了治疗诸如再狭窄的病症，将不同的药剂装入装置中的不同开口以解决与再狭窄相关的不同生物过程，并且以与所治疗的生物过程相匹配的不同释放动力学递送。 不同的药剂也可用于解决来自同一药物递送装置的不同疾病。 此外，抗血栓形成剂可以附着在医疗装置的至少一部分表面上，以防止亚急性血栓形成。 为了确保不同的试剂保持固定在装置上以及彼此之间，可以使用底漆层。